Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8911786 | AADI | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Feb, 2029
(5 years from now) | |
US10206887 | AADI | Prion free nanoparticle compositions and methods of making thereof |
Apr, 2030
(7 years from now) | |
US10705070 | AADI | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
Mar, 2036
(12 years from now) | |
US10973806 | AADI | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Jun, 2036
(13 years from now) | |
US11497737 | AADI | NA |
Oct, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Nov 22, 2024 |
Orphan Drug Exclusivity (ODE) | Nov 22, 2028 |
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle
Dosage: POWDER;INTRAVENOUS
35
United States
12
Japan
9
European Union
8
Korea, Republic of
5
Portugal
5
Spain
5
Croatia
5
China
5
Lithuania
5
Canada
5
Hungary
5
Slovenia
5
Poland
5
Australia
5
Denmark
4
Russia
4
Brazil
4
New Zealand
4
Israel
3
Mexico
3
Cyprus
2
Singapore
2
EA
2
South Africa
2
Ukraine
2
RS
1
Malaysia
1
Argentina
1
Taiwan, Province of China
1
Hong Kong
1
ME
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic